- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02603926
Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study includes a screening visit with several assessments, followed by an open-label medication trial of Allopregnanolone for 12 weeks and an end-point evaluation to assess for changes. Assessments include blood draws for genetic and safety laboratory testing, neurological and physical exam and medical history, cognitive testing, and motor testing.
Study record was updated in October 2018 to include adverse events and outcome measure reporting. Study record was updated in November 2018 in response to requests to (1) specify time frame of reported outcome measures, (2) clarify that the RASS was a safety monitoring tool, not a prespecified outcome measure, and as such will not be reported as an outcome measure, and (3) upload a version of the study protocol and statistical analysis plan with the required title page and statistical analysis plan information.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- UC Davis MIND Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Fragile X premutation carrier status (55 to 200 CGG repeats in FMR1),
- Diagnosis of FXTAS including an intention tremor and/or ataxia and/or deficits on the BDS-2 demonstrating executive function deficits.
Exclusion Criteria
- other genetic problems in addition to the premutation
- a history of significant brain trauma
- significant substance abuse
- inability to follow the protocol
- liver or kidney disease
- heart failure
- active cancer
- other serious systemic disease
- current use of phenytoin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Allopregnanolone
Subjects will receive an intravenous infusion of Allopregnanolone at escalating doses of 2mg, 4mg, and 6mg once weekly over a three week period.
The highest dose tolerated without sedation will be held stable for the remaining weekly infusions, for a total of 12 infusions.
|
Allopregnanolone is an endogenous inhibitory pregnane neurosteroid.
It is synthesized from progesterone, and is a potent positive allosteric modulator of the action of γ-aminobutyric acid at GABAA receptor.
Subjects will receive up to 12 infusions in the study.
Subjects will all begin with 2.0 mg dosage.
If tolerated, the next infusion will be 4.0 mg, and if that is tolerated, the next infusion will be 6.0 mg.
Subject infusions will remain stable at the highest dosage tolerated for the remainder of the study.
Each infusion will consist of 2.0 mg, 4.0 mg, or 6.0 mg aliquots of the 0.5 mg/ml allopregnanolone in 6% sulfobutylether-β-cyclodextrin with 0.9% sodium chloride injection solution.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
California Verbal Learning Test II (CVLT2) Trial 1-5 Free Recall Total Raw Score
Time Frame: Baseline/pre-treatment and 14 weeks/post-treatment
|
California Verbal Learning Test II (CVLT2) is an assessment measuring working memory.
Trials 1-5 measure the total number of words remembered after 5 repeated trials and are summed to generate a raw score (called Trial 1-5 Free Recall Total Raw Score) ranging from 0 to 80, with higher scores reflecting better working memory.
Mean and standard deviation for raw score at baseline/pre-treatment and at 14 weeks/post-treatment are presented here.
|
Baseline/pre-treatment and 14 weeks/post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Behavioral Dyscontrol Scale - 2 (BDS-2) Total Score
Time Frame: Baseline/pre-treatment and 14 weeks/post-treatment
|
The BDS-2 is a validated 9-item assessment measuring the ability to regulate purposeful, goal-directed activity and to engage in activities of daily living, with focus on motor items.
Each of the 9 items is scored on a scale of 0 to 3, resulting in a summed total score ranging from 0 to 27.
Higher scores reflect fewer errors and stronger ability to regulate motor activities.
Mean and standard deviation for total score at baseline/pre-treatment and at 14 weeks/post-treatment are presented here.
|
Baseline/pre-treatment and 14 weeks/post-treatment
|
CATSYS Dot-to-Dot Tremor Intensity (CATSYS DTD TI)
Time Frame: Baseline/pre-treatment and 14 weeks/post-treatment
|
The CATSYS system is a portable device recording various measures of neuromotor control, including tremor.
The CATSYS Dot-to-Dot Tremor Intensity (DTD TI) protocol quantifies tremor by having a participant hold a tremor pen as they would an ordinary pen, with the elbow joint bent at a right angle and free of body contact, and the pen positioned approximately 4 inches from the navel.
Subjects are instructed to use the pen first to tap the center of two circular stickers, approximately 0.5 inch in diameter, placed on opposite ends of the bottom portion of the computer monitor; then, subjects are instructed to trace a line across the table using the tremor pen.
The pen is connected to a computer with sensors that measure tremor intensity (TI) in units of meters per second (m/s).
Larger values reflect greater tremor intensity.
Mean right-hand and left-hand TI and standard deviation at baseline/pre-treatment and at 14 weeks/post-treatment are reported here.
|
Baseline/pre-treatment and 14 weeks/post-treatment
|
Hippocampal Volume, as Measured by Structural MRI
Time Frame: Baseline/pre-treatment and 14 weeks/post-treatment
|
Patients will undergo structural Magnetic Resonance Imaging (MRI) at baseline/pre-treatment and at 14 weeks/post-treatment.
The MRI is interpreted by a trained clinician and hippocampal volume in cubic centimeters is measured and recorded.
Larger values reflect greater volumes of the hippocampus, and greater hippocampal volume post-treatment may be indicative of increased neurogenesis.
Mean hippocampal volume and standard deviation at baseline/pre-treatment and post-treatment is reported here.
|
Baseline/pre-treatment and 14 weeks/post-treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Randi J Hagerman, MD, UC Davis MIND Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Disease
- Dyskinesias
- Cerebellar Diseases
- Syndrome
- Ataxia
- Tremor
- Cerebellar Ataxia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Anesthetics
- GABA Modulators
- GABA Agents
- Neurosteroids
- Brexanolone
- Pregnanolone
Other Study ID Numbers
- 720668
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fragile X-associated Tremor/Ataxia Syndrome
-
University of California, DavisCompletedFragile X Associated Tremor/Ataxia Syndrome (Fxtas) (Diagnosis)United States
-
University of California, DavisNational Institute on Aging (NIA); Forest LaboratoriesCompletedFragile X-Associated Tremor/Ataxia Syndrome | Fragile X Premutation CarriersUnited States
-
Rush University Medical CenterTerminatedFragile X Associated Tremor-ataxia SyndromeUnited States
-
Sheba Medical CenterElMindA LtdRecruitingFragile X Associated Tremor-ataxia Syndrome | FXTASIsrael
-
Rush University Medical CenterCompletedFragile X Tremor/Ataxia SyndromeUnited States
-
Ovid Therapeutics Inc.CompletedFragile X Syndrome (FXS)United States
-
Guido A. Davidzon, MD, SMWithdrawn
-
Marinus PharmaceuticalsUniversity of California, Davis; U.S. Army Medical Research and Development...Completed
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedFragile X Syndrome (FXS)United States
-
Novartis PharmaceuticalsTerminated
Clinical Trials on Allopregnanolone
-
Michael A. Rogawski, MD, PhDUnited States Department of DefenseCompletedTraumatic Brain Injury | Posttraumatic EpilepsyUnited States
-
Roberta BrintonRecruitingParkinson DiseaseUnited States
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
University of ArizonaUniversity of Southern California; Alzheimer's AssociationActive, not recruitingAlzheimer DementiaUnited States
-
VA Office of Research and DevelopmentNot yet recruitingTraumatic Brain Injury (TBI)United States
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Sage TherapeuticsCompletedPostpartum DepressionUnited States
-
Sage TherapeuticsTerminatedCOVID-19 | Acute Respiratory Distress SyndromeUnited States
-
Sage TherapeuticsCompleted
-
Boston UniversityNational Institute of Mental Health (NIMH)RecruitingPost Traumatic Stress DisorderUnited States